Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying new signaling mediators responsible for Mesothelin (MSLN) intraperitoneal (IP) tumor growth phenotype

ABSTRACT: Identifying new signaling mediators responsible for Mesothelin (MSLN) intraperitoneal (IP) tumor growth phenotype

PROVIDER: PRJNA544323 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9110350_1.fastq.gz	Fastqsanger.gz
	SRR9110350_2.fastq.gz	Fastqsanger.gz
	SRR9110360_1.fastq.gz	Fastqsanger.gz
	SRR9110360_2.fastq.gz	Fastqsanger.gz
	SRR9110370_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 50

Similar Datasets

Identifying new signaling mediators responsible for Mesothelin (MSLN) intraperitoneal (IP) tumor growth phenotype

Project description:Identification of new targets involved in MSLN signaling by comparing mRNA expression patterns in MSLN WT and KO in both cells grown in culture and in IP tumor tissues using RNA deep sequencing

2020-05-23 | GSE131664 | GEO

Structure of Cancer Antigen Mesothelin and Its Complex with Therapeutic Antibodies

Project description:Mesothelin is a differentiation antigen expressed at high levels on the surface of many cancers; its interaction with cancer antigen CA-125 can lead to metastasis. Mesothelin has been the subject of intensive investigations as a potential cancer antigen for immunotherapy. Structures of a fragment of mesothelin, full-length mesothelin alone and in complex with the Fab fragment of the therapeutic antibody MORAb-009, as well as a complex of its C-terminal fragment containing the majority of the identified shedding sites, or the shedding-resistant fragment, with monoclonal antibody 15B6 were obtained. The glycosylation profile of mesothelin purified from A431/H9 cells and patient ascites were obtained by glycoproteomics

2023-05-10 | PXD034397 | Pride

RNA-Seq of mice omenta after intraperitoneal (IP) or systemic delivery (IV) of tumor-specific T cells

Project description:RNA-Seq of mice omenta after intraperitoneal (IP) or systemic delivery (IV) of tumor-specific T cells

| PRJNA811177 | ENA

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [III]

Project description:The immune system is active in the tumor microenvironment (TME) of epithelial ovarian cancer (EOC) and carries both effector and suppressive functions. We profiled biomarker expression on serial biological specimens collected during intraperitoneal (IP) chemotherapy to better define treatment-induced tumor involution.

2023-06-02 | GSE217178 | GEO

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [II]

2023-06-02 | GSE217177 | GEO

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [I]

2023-06-02 | GSE217175 | GEO

Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators

Project description:Aim of the study is to ascertain whether a different strategy of fluids administration can be responsible of differences in terms of acid/base disorders (Stewart approach), pro-inflammatory and inflammatory mediators. Hence two groups of patients will be treated either with not-balanced solutions (Normal Saline) or balanced solutions

| 2104179 | ecrin-mdr-crc

Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma

Project description:Appendiceal adenocarcinomas (AAs) are a rare and heterogeneous mix of tumors for which few preclinical models exist. The rarity of AA has made performing prospective clinical trials difficult, which has partly contributed to AA remaining an orphan disease with no chemotherapeutic agents approved by the FDA for its treatment. AA has a unique biology in which it frequently forms diffuse peritoneal metastases but almost never spreads via a hematogenous route and rarely spreads to lymphatics. Given the localization of AA to the peritoneal space, intraperitoneal (IP) delivery of chemotherapy could be an effective treatment strategy. Here, we tested the efficacy of paclitaxel given by IP administration using three orthotopic patient-derived xenograft (PDX) models of AA established in immunodeficient NSG mice. Weekly IP paclitaxel treatment dramatically reduced AA tumor growth in all three PDX models. Comparing the safety and efficacy of intravenous (IV) to IP administration, IP delivery of paclitaxel was more effective with reduced systemic side effects in mice. Given the established safety record of IP paclitaxel in gastric and ovarian cancers, and lack of effective chemotherapeutics for AA, these data showing the activity of IP paclitaxel in orthotopic PDX models of mucinous AA support the evaluation of IP paclitaxel in a prospective clinical trial.

2023-07-07 | GSE236502 | GEO

MTG1-RNA IP

Project description:MTG1-RNA IP

| PRJNA479873 | ENA

TAP RNA-IP - ZC3H22

Project description:TAP RNA-IP - ZC3H22

| PRJEB27340 | ENA